MRC1 and neoplasm: Most of the tumors were located in the left colon (79.7%); 78.8% (905/1148) of patients had a moderately differentiated tumor and 69.9% (803/1148) were either stage II or stage III; 9.2% (106/1148) of tumors were MMR deficient by immunohistochemistry; 3.0% (34/1148) of tumors in our cohort were BRAF mutant.